Challenges and new discoveries in the treatment of leishmaniasis

https://doi.org/10.1007/s10156-004-0348-9Get rights and content

Abstract

Leishmaniasis is a parasitic disease caused by a hemoflagellate, Leishmania spp. The parasite is transmitted by the bite of an infected female phlebotomine sandfly. The disease is prevalent throughout the world and in at least 88 countries. Human leishmanial infections may manifest in any of the four most common forms. Depending on the causative species, it can manifest as cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), diffused cutaneous leishmaniasis (DCL), or visceral leishmaniasis (VL). Although there are nearly 25 compounds having antileishmanial effects, only a few are used for humans and most of these are parenteral. The oldest was urea stibamine, developed in India in 1922. The original drug had severe toxic effects, and later on its pentavalent compounds were prepared, which remained the sole treatment modality for several decades and saved millions of lives. However, reports of unresponsiveness to pentavalent sodium antimony gluconate (SAG) started in the 1970s, and in some parts of India about a quarter of kala-azar cases are reported to have developed resistance even to its higher doses. This development led to successful clinical trials of pentamidine and amphotericine B. The latter, an antifungal compound, was also found to be highly nephrotoxic, and to minimize these side effects various colloidal and lipid formulations have been prepared. These preparations are comparatively safe but are exorbitantly costly. In the past two decades, more focus has been given to finding oral drugs to minimize injection-associated complications, including blood-borne infection. Various drugs were reported effective, including antifungal ketoconazole. However, the most promising drug found is an anticancer compound, miltefosine, that belongs to the alkylphosphocholine group. The drug has undergone experimental and clinical trials and found to be 94%–97% effective. However, the drug cannot be given during pregnancy and shows severe gastrointestinal side effects. Moreover, its cost will be another limiting factor. Other drugs such as paromomycin, allopurinol, and sitamaquine have been reported with variable cure rates. Because of these limitations, a combination therapy, preferably coupled with specific parasite enzyme inhibitors, is the only hope.

References (64)

  • S. Sundar et al.

    Treatment of kala-azar with oral fluconazole

    Lancet

    (1996)
  • K. Seifert et al.

    Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)

    Int J Antimicrob Agents

    (2003)
  • J. El-On et al.

    Topical treatment of cutaneous leishmaniasis

    J Invest Dermatol

    (1986)
  • A.D. Bryceson et al.

    Treatment of “Old World” cutaneous leishmaniasis with aminosidine ointment: results of an open study in London

    Trans R Soc Trop Med Hyg

    (1994)
  • S. Singh

    Mucosal Leishmaniasis in an Indian AIDS patient

    Lancet Infect DIS

    (2004)
  • Geographical distribution of leishmaniasis. Geneva: WHO. Available at:...
  • (1990)
  • W. Peter

    The treatment of kala-azar: new approach to an old problem

    Ind J Med Res

    (1981)
  • R.K. Sanyal

    Leishmaniasis in the Indian subcontinent

  • V. Ramesh et al.

    Post-kala-azar dermal leishmaniasis

    Int J Dermatol

    (1995)
  • R. Paredes et al.

    Leishmaniasis in HIV infection

    J Postgrad Med

    (2003)
  • S. Singh et al.

    Transfusion-transmitted Kala-azar in India

    Transfusion

    (1996)
  • C.P. Thakur et al.

    Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study

    Am J Trop Med Hyg

    (1991)
  • C.P. Thakur

    Drug resistance in kala-azar: an overviews

  • B.L. Herwaldt et al.

    Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies

    Am J Trop Med Hyg

    (1992)
  • J.D. Berman

    Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

    Clin Infect Dis

    (1997)
  • R.A. Gasser et al.

    Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis

    Clin Infect Dis

    (1994)
  • C.F. Brummitt et al.

    Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis

    Clin Infect Dis

    (1996)
  • S.N. Jha et al.

    Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial

    J Assoc Physicians India

    (1991)
  • J. Soto et al.

    Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine

    Am J Trop Med Hyg

    (1994)
  • S. Sundar

    Treatment of visceral leishmaniasis

    Med Microbiol Immunol (Berl)

    (2001)
  • C.P. Thakur et al.

    Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life

    Indian J Pediatr

    (1993)
  • Cited by (256)

    • Leishmaniasis

      2022, Encyclopedia of Infection and Immunity
    View all citing articles on Scopus
    View full text